A Phase 2, Randomized, Double-Blinded Study of the Safety and Efficacy of GS-9883 + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Trial Profile

A Phase 2, Randomized, Double-Blinded Study of the Safety and Efficacy of GS-9883 + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Oct 2017

At a glance

  • Drugs Bictegravir (Primary) ; Emtricitabine/tenofovir alafenamide (Primary) ; Dolutegravir
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 08 Oct 2017 Results presented at the IDWeek 2017
    • 30 Jun 2017 Planned End Date changed from 1 Feb 2018 to 1 Jan 2019.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top